Advanced search
1 file | 79.11 KB Add to list

Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

(2008) KIDNEY INTERNATIONAL. 74(10). p.1237-1240
Author
Organization
Abstract
The development of clinical practice guidelines for the treatment of anemia in chronic kidney disease has been instrumental in identifying and reducing variations in the use of erythropoiesis-stimulating agents and iron replacement. Challenges to the effectiveness and safety of recommendations made in these guidelines were magnified when recent clinical trials showed no benefit or harm with respect to cardiovascular outcomes in subjects randomized to higher target hemoglobin levels. To address these concerns, Kidney Disease: Improving Global Outcomes (KDIGO) convened an international conference to examine the problems and shortcomings of existing anemia guidelines, which are a prime example of duplication of efforts to derive recommendations from a limited evidence base. The meeting was attended by representatives of the major guideline developing organizations, who agreed to avoid future duplicative efforts and to save resources in generating a common evidence report, whose recommendations could then be prioritized and implemented locally. This is a report to the international nephrology community of the recommendations for and timeline of the next anemia guidelines. It has been reviewed by the conference participants and approved as a position statement by the KDIGO Board of Directors.
Keywords
guidelines, hemoglobin, chronic kidney disease, UPDATE, anemia, dialysis, HEMODIALYSIS-PATIENTS, EPOETIN

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 79.11 KB

Citation

Please use this url to cite or link to this publication:

MLA
Locatelli, Francesco et al. “Clinical Practice Guidelines for Anemia in Chronic Kidney Disease: Problems and Solutions. A Position Statement from Kidney Disease: Improving Global Outcomes (KDIGO).” KIDNEY INTERNATIONAL 74.10 (2008): 1237–1240. Print.
APA
Locatelli, F., Nissenson, A. R., Barrett, B. J., Walker, R. G., Wheeler, D. C., Eckardt, K. U., Lameire, N., et al. (2008). Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). KIDNEY INTERNATIONAL, 74(10), 1237–1240.
Chicago author-date
Locatelli, Francesco, Allen R. Nissenson, Brendan J. Barrett, Rowan G. Walker, David C. Wheeler, Kai U. Eckardt, Norbert Lameire, and Garabed Eknoyan. 2008. “Clinical Practice Guidelines for Anemia in Chronic Kidney Disease: Problems and Solutions. A Position Statement from Kidney Disease: Improving Global Outcomes (KDIGO).” Kidney International 74 (10): 1237–1240.
Chicago author-date (all authors)
Locatelli, Francesco, Allen R. Nissenson, Brendan J. Barrett, Rowan G. Walker, David C. Wheeler, Kai U. Eckardt, Norbert Lameire, and Garabed Eknoyan. 2008. “Clinical Practice Guidelines for Anemia in Chronic Kidney Disease: Problems and Solutions. A Position Statement from Kidney Disease: Improving Global Outcomes (KDIGO).” Kidney International 74 (10): 1237–1240.
Vancouver
1.
Locatelli F, Nissenson AR, Barrett BJ, Walker RG, Wheeler DC, Eckardt KU, et al. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). KIDNEY INTERNATIONAL. 2008;74(10):1237–40.
IEEE
[1]
F. Locatelli et al., “Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO),” KIDNEY INTERNATIONAL, vol. 74, no. 10, pp. 1237–1240, 2008.
@article{746880,
  abstract     = {The development of clinical practice guidelines for the treatment of anemia in chronic kidney disease has been instrumental in identifying and reducing variations in the use of erythropoiesis-stimulating agents and iron replacement. Challenges to the effectiveness and safety of recommendations made in these guidelines were magnified when recent clinical trials showed no benefit or harm with respect to cardiovascular outcomes in subjects randomized to higher target hemoglobin levels. To address these concerns, Kidney Disease: Improving Global Outcomes (KDIGO) convened an international conference to examine the problems and shortcomings of existing anemia guidelines, which are a prime example of duplication of efforts to derive recommendations from a limited evidence base. The meeting was attended by representatives of the major guideline developing organizations, who agreed to avoid future duplicative efforts and to save resources in generating a common evidence report, whose recommendations could then be prioritized and implemented locally. This is a report to the international nephrology community of the recommendations for and timeline of the next anemia guidelines. It has been reviewed by the conference participants and approved as a position statement by the KDIGO Board of Directors.},
  author       = {Locatelli, Francesco and Nissenson, Allen R. and Barrett, Brendan J. and Walker, Rowan G. and Wheeler, David C. and Eckardt, Kai U. and Lameire, Norbert and Eknoyan, Garabed},
  issn         = {0085-2538},
  journal      = {KIDNEY INTERNATIONAL},
  keywords     = {guidelines,hemoglobin,chronic kidney disease,UPDATE,anemia,dialysis,HEMODIALYSIS-PATIENTS,EPOETIN},
  language     = {eng},
  number       = {10},
  pages        = {1237--1240},
  title        = {Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)},
  url          = {http://dx.doi.org/10.1038/ki.2008.299},
  volume       = {74},
  year         = {2008},
}

Altmetric
View in Altmetric
Web of Science
Times cited: